MTX exerted specific anti-inflammatory actions, reducing aortic endothelial and adventitial ICAM-1 and preventing leucocytic infiltration of the arterial wall, suggesting an additional mechanism by which MTX may retard CV events in RA. The gene discussed is ICAM1; the disease is rheumatoid arthritis.